Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2
Abstract
To enable benchmarking of immunogenicity between candidate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there is a need for standardized, validated immunogenicity assays. In this article, we report the design and criteria used to validate immunogenicity assays and the outcome of the validation of serologic and functional assays for the evaluation of functional immune response and antibody titers in human serum.
Click here to download the full article
In association with:
Source: Bonhomme ME, Bonhomme CJ, Strelow L, et al. (2022) Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. PLoS ONE, 17(2) doi: 10.1371/journal.pone.0262922 (2022)
This article is a part of the Bioanalysis Zone Spotlight feature on vaccine assay development. For more expert opinions on this topic, visit our feature homepage